OUHSC Research News – Monday, November 22, 2021
Notices and Reminders
In alignment with the University’s closure for the upcoming holidays, the Office of the Vice President for Research (VPR) will be closed for:
Thanksgiving Break – The Office of the VPR including ORA will be closed Thursday, November 25, 2021 and Friday, November 26, 2021, reopening on Monday, November 29, 2021.
Winter Break – The Office of the VPR including ORA will be closed on December 23, 2021 through December 31, 2021, reopening on January 3, 2022.
Any proposals or other items due to sponsors during this time must be submitted to ORA within three business days before the campus closure dates. Any contracts expiring December 31, 2021 need to be in our office by December 13, 2021. Should you need urgent assistance during the holiday closure, please contact ORA at HSCORA@ouhsc.edu. All other matters will be addressed when the University reopens for regular business hours.
Effective October 1st, the NIH requires all NIH-funded clinical trials to complete clinical trial registration 21 days after enrollment of first participant and/or results reporting 12 months after trial actual primary completion date. NIH has now enhanced checks on non-compliance for these two requirements in the eRA System. Failure to comply with NIH timeline will delay your Research Performance Progress Report (RPPR) submission. NIH has also placed additional scrutiny on all aspects of RPPRs that has resulted in a significant increase in rejected reports from OUHSC investigators.
Because of these substantial changes and additional information requirements (including Other Support format), all RPPRs are now subject to additional review by ORA.
Effective January 1, 2022, ORA MUST receive RPPRs for review 3 business days prior to the sponsor deadline for single-project grants and 5 business days prior to the sponsor deadline for multi-project grants.
For more information on NIH enhanced checks on non-compliance, please see: https://nexus.od.nih.gov/all/2021/11/09/enhanced-checks-for-compliance-with-clinical-trial-registration-and-reporting-in-rppr/
ORA announces a one-month trial of SPINPlus, a comprehensive funding opportunities database by InfoEd Global
ORA has secured a one-month trial of SPINPlus, the world’s largest funding opportunities database. SPINPlus includes the SPIN database of funding opportunities and matching alert service called SMARTS. With SPINPlus, OUHSC researchers, administrators, postdocs, and graduate students can search over 40,000 funding opportunities from more than 12,000 federal, public, non-profit, and private sponsors and create automated alert service, which delivers targeted funding opportunities via email.
Please contact Sogol Rasouli at firstname.lastname@example.org to find out how to register and access SPINPlus, and set up your own funding alerts.
ORA Reminder: Effective October 1st, ORA requires applicants and recipients to use the updated Other Support format to submit with applications, Just-In-Time (JIT) and Research Performance Progress Reports (RPPRs).
Because of the substantial changes and additional information that needs to be included, all Key Personnel on RPPRs are expected to provide Other Support in the updated format for each RPPR, regardless of when Other Support was last submitted for key personnel. Failure to follow the appropriate format on or after October 1st, may delay processing your application/award by the ORA staff.
ORA Reminder: As a friendly reminder, please make sure you are carefully checking PeopleSoft and the budget justification to make sure OU Norman personnel are not included in the OUHSC personnel line. Failure to properly list the OUHSC vs Norman personnel in the budget preparation phase may result in a rebudget request from the sponsor, and could negatively impact processing of the award.
Requirements for Acknowledging NIH-Supported Research
NIH funded researchers are required to accurately acknowledge NIH funding in publications, press releases, or other documents about research that is funded by NIH in whole or in part. To comply with NIH requirements, recipients must include the following (as described in Communicating and Acknowledging Federal Funding):
Recipients should only acknowledge NIH awards on publications and other documents when the research activities that contributed to that publication directly arise from the award and are within the scope of the award being acknowledged. Please see the Communicating and Acknowledging Federal Funding and FAQs pages for more information on when, where, and how to acknowledge NIH funding.
Workshops and Seminars
Save the Date - ORA Noon Conference offered via Zoom
Date: November 30, 2021 at 1:00 pm
Topic: Writing Successful Grants
Description: This talk goes beyond the basics of grant writing to discuss writing the specific aims and considerations for the research strategy, convey the NIH-recommended format and approach for each subsection, address and explain core-review criteria, and discuss scoring conventions, rigor, and reproducibility.
The OU Stephenson Cancer Center 2021 END2CANCER: Emerging Nanotechnology and Drug Delivery Applications for Cancer conference
Date: December 2-3, 2021, via Zoom
Description: The OU Stephenson Cancer Center is proud to host the 2021 END2CANCER: Emerging Nanotechnology and Drug Delivery Applications for Cancer conference. The END2CANCER conference will start the morning of December 2, 2021 and conclude in the afternoon of December 3, 2021. The conference will bridge laboratory research conducted in the areas of nanotechnology and drug delivery to clinical application for the detection, diagnosis, imaging and treatment of cancer. The conference will host keynote, plenary and invited lectures by eminent scientists who will discuss new and emerging concepts, technologies and challenges in translating nanomedicine from bench-to-bedside.
OUHSC Funding Opportunities
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email email@example.com or firstname.lastname@example.org).
- A global medical device company (requested anonymity) is interested in innovations for minimally invasive interventional treatment for chronic kidney disease and underlying conditions. Out of scope: dialysis modalities. Submission entails a 1-pg non-confidential summary of technology (deadline 12/1).
- A global hygiene company (requested anonymity) is seeking research focused on in situ generation of biologically (microbe or enzyme) generated antimicrobials. Of highest interest are opportunities where the agent produced is already registered as a biocidal active agent, safety and efficacy testing have been conducted, clear regulatory pathway strategy, and data demonstrating long-lasting effect/colonization effects of the technology. Submission entails a 1-pg non-confidential summary of technology (deadline 12/1).
- A global hygiene company (requested anonymity) is seeking novel ingredients for modulating skin microbiome benefits for non-pharmaceutical consumer use. Of highest interest are ingredients for bar soap, hand/body wash, cream/serum, or alcohol based hand sanitizer. Submission entails a 1-pg non-confidential summary of technology (deadline 12/1).
- Travere Therapeutics is seeking an academic research collaboration focused on polycystic kidney disease (ADPKD, ARPKD). Out of scope: drug repurposing, diagnostics. Preference is for opportunities with evidence of novel mechanism and POC data. Submission entails a 1-pg non-confidential summary of technology (deadline 1/5).
New Clinical Study Opportunities (Please note this is NOT a solicitation for study subjects)
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
- Clinical Trial Opportunity in Sickle Cell Disease study - IQVIA Biotech LLC
- Valo Health Phase 2 Cardiovascular Trial For Post-Myocardial Infarction Patients
- Phase 2 Acute Myeloid Leukemia (AML) Clinical Trial
Please contact Scott Davis at email@example.com if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.
- Notice of Informational Webinar on the NIGMS PREP Program PAR-20-066, "Postbaccalaureate Research Education Program (R25)"
- Notice of Informational Webinar on the NIGMS IMSD and G-RISE Research Training Programs
- Notice of Availability of Pre-Application Webinar Recording and FAQ for RFA-MH-22-100 Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries
- Notice of Pre-Application Webinar for RFA-MH-22-120, "Pilot Practice-based Research for Primary Care Suicide Prevention (R34 Clinical Trial Optional)"
- Notice of Pre-Application Webinar for Cellular Senescence Network (SenNet) RFAs: RFA-RM-22-003, RFA-RM-22-004, RFA-RM-22-005
- Request for Information: Seeking Input from Cohort and Biorepository Researchers on Liquid Biopsy Studies for Early Cancer Detection
- Request for Information: Seeking Input from Technology Developers on Liquid Biopsy Studies for Early Cancer Detection
- Request for Information (RFI) on the NINR 2022-2026 Strategic Plan Framework
- Notice of Correction to PAR-21-035, Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trials Required)".
- Notice of Early Expiration of NOT-HL-20-755 "Notice of Special Interest (NOSI): Heart, lung, blood and sleep focused ancillary studies to large ongoing clinical studies"
- Notice of Change to Application Due Dates for PAR-21-281, "Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 - Clinical Trials Not Allowed)"
- Notice of Change to Review Dates of PAR-22-054, Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
- Notice of Change to Receipt Date for CTSA Program Funding Opportunities: PAR-21-293 (UM1), PAR-21-336 (K12), PAR-21-340 (RC2), PAR-21-339 (R25), PAR-21-338 (T32), and PAR-21-337 (T32)
- Notice of Change to Expansion of Eligibility of Optional Companion Applications for CTSA Program Funding Opportunities: PAR-21-293 (UM1), PAR-21-340 (RC2), PAR-21-339 (R25), PAR-21-338 (T32), and PAR-21-337 (T32)
- Notice of Change to PI effort and eligibility of foreign components for PAR-21-336: Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional)
- Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R01 Clinical Trial Optional)
- Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R21 Clinical Trial Optional)
- Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R34 Clinical Trial Optional)
- Notice of Special Interest: Administrative Supplements for Summer Research Experiences for Students and Science Teachers
- Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)
- Notice of Special Interest: SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed)
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
Other Funding Opportunities
Diabetes Research Wellness Foundation – Research Grants
Description: DRWF accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to $50,000 per year for up to 2 years. If the proposed research is within an area of primary interest and is judged as having high scientific merit by the Foundation’s advisors, the Board of Directors may make special grant awards that exceed the stated maximum. Currently, the Foundation’s area of primary interest and focus are islet cell transplantation, macrovascular disease & neuropathy. All other research proposals will not be reviewed.
Proposals Due: December 30, 2021
Link to Full Announcement: https://www.diabeteswellness.net/apply-funding
Mary Kay Ash Foundation 2022 Cancer Research Grants
Description: The Mary Kay Ash FoundationSM is a non-profit public foundation, which focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others). Translational research is broadly defined as research that will provide a scientific link between laboratory research and the clinic. Such research would lead to improvement in diagnosis, prognosis, prevention, or treatment of the cancer. The Foundation is pleased to invite your institution to submit one grant proposal. Please note only one grant application will be accepted from each accredited, invited institution.
The grant will be up to $100,000 (combined direct and indirect costs) for a two-year period. The Foundation anticipates funding between 10 and 15 grants. Please review the attached RFP with FAQs section as well as the Applicant User Guide for additional information.
Proposals Due: February 4, 2022 at 11:59 PM (CT)
Please complete your application here: https://apply.yourcausegrants.com/apply/programs/7d085160-a542-4415-bea4-1fbe139b51ee
Please reach out to Julia Santosuosso if you have any questions at Julia.Santosuosso@mkcorp.com.
The American Heart Association (AHA) - Request for Applications (RFA) for a Strategically-Focused Research Network (SFRN) on the Science of Diversity in Clinical Trials (SDCT).
Description: With the establishment of the SFRN on the Science of Diversity in Clinical Trials, the AHA will identify solutions underlying the inequitable participation of diverse individuals in clinical research, and the associated health inequities it creates.
The network will consist of at least three Network Centers, each of which will propose novel research strategies to engage individuals from under-represented groups in clinical trials such that their participation in clinical trials aligns with the diversity of our communities. Each Network Center application will include two or three research projects with a common fundamental theme that will assess an intervention or approach to addressing diversity in clinical trials and must have the necessary research team, required infrastructure and ability to recruit and retain a diverse group of study participants. Each center may request up to $4.3 million over four years.
In addition, a Training Center will be established as part of the Network to incorporate a multidisciplinary approach to provide robust research experiences, training, and mentorship for Center Fellows. All SDCT Fellows will be from groups who are under-represented in science and medicine. The maximum budget amount a Training Center applicant may request is $500,000 over four years.
Pre-proposals Due: December 7, 2021
Link to Full Announcement: https://professional.heart.org/en/research-programs/strategically-focused-research/strategically-focused-research-networks/2022-science-of-diversity-in-clinical-trials-research-network
Cystic Fibrosis Foundation
The following RFAs have a full application deadline of December 9, 2021:
Additional Open Funding Opportunities can be found at https://cff.org/Research/Researcher-Resources/Awards-and-Grants/Funding-Opportunities/
Asahi Kasei Pharma Call for Collaboration proposal
Description: Asahi Kasei Pharma is publicly calling for new proposals related to drug discovery research as part of its efforts for open innovation, to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes, and enterprises around the world. Proposals are solicited concerning new drug seeds (drug target and drug candidate) and technologies in the therapeutic fields of autoimmune disease, critical care medicine, neurodegenerative disease, pain and neuropathy, bone disease, and drug discovery platform technology.
Submissions will be assessed for their potential for collaborative research.
Proposals Due: February 28, 2022
Link to Full Announcement: www.asahikasei-pharma.co.jp/a-compass/en/
Chan Zuckerberg Initiative (CZI) Single-Cell Biology Data Insights RFA
Description: Given the growth of the single-cell biology field and the rapid increase in available data, the Chan Zuckerberg Initiative (CZI)’s newest funding opportunity seeks to support computational experts to advance tools and resources that make it possible to gain greater insights into health and disease from existing single-cell biology datasets. The CZI Single-Cell Biology Data Insights Request for Applications (RFA) invites applications for projects that will advance the fields of single-cell biology and data science. Projects should address computational challenges and bottlenecks associated with boosting the utility and insight from available single-cell biology datasets. Projects may include dedicated efforts to improve existing computational tools and standards, benchmarking classes of tools, integration of available datasets to enable greater biological insight, development of new features that support interoperability of current data or tools, and other major challenges brought forward.
Proposals Due: December 14, 2021
Link to Full Announcement: https://chanzuckerberg.com/rfa/single-cell-data-insights/
Oklahoma Center for Adult Stem Cell Research (OCASCR)
Grant Deadline: January 28, 2022